Target intelligence / Profile preview

Macronutrient absorption

Molecular classification
Transporter, Enzyme
01

Overview

Macronutrient absorption refers to the physiological process in the small intestine where carbohydrates, proteins, and fats from digested food are taken up by enterocytes primarily through transcellular transport mechanisms involving specific enzymes and transporters. Carbohydrates are broken down by brush-border enzymes like sucrase, maltase, and lactase into monosaccharides such as glucose, which are absorbed via sodium-glucose linked transporter 1 (SGLT1) or facilitated diffusion (e.g., GLUT5 for fructose); proteins are degraded by gastric pepsin, pancreatic proteases (trypsin, chymotrypsin), and peptidases into amino acids and di/tripeptides, absorbed mainly via PEPT1 proton-coupled transport; fats are emulsified by bile salts, hydrolyzed by pancreatic lipase into fatty acids and monoglycerides, and absorbed via micelles into enterocytes for chylomicron packaging. This process is essential for energy homeostasis but disruptions lead to malnutrition or metabolic disorders like obesity. While not a single molecular target, components such as SGLT1, PEPT1, and pancreatic lipase are modulated by drugs: liraglutide indirectly reduces absorption via delayed gastric emptying, orlistat blocks lipase, and acarbose inhibits carb-digesting enzymes, offering therapeutic avenues for obesity/diabetes management but posing risks like gastrointestinal side effects and vitamin malabsorption.

Other names
Intestinal nutrient absorptionSmall intestine absorptionEnterocyte nutrient uptakeMacronutrient digestion and uptake
02

Mechanism of action

Inhibition of pancreatic lipase, Blockade of brush-border enzymes, Interference with sodium-coupled transporters

03

Biological functions

Digestion of carbohydrates/proteins/fatsNutrient uptake into enterocytesIon-coupled transportMicelle-mediated lipid absorption
04

Disease associations

MalnutritionObesityCystic fibrosis (chloride-related)Short bowel syndromePancreatic insufficiency
05

Safety considerations

Steatorrhea/diarrhea (fat malabsorption)Flatulence/bloating (carb malabsorption)Nutrient deficiencies (long-term inhibition)Electrolyte imbalances
06

Interacting drugs

Orlistat (lipase inhibitor)

2 more in the full profile.

Beyond the preview

Go deeper on Macronutrient absorption.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macronutrient absorption.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call